Melanotan II: synthetic tanning & sexual-arousal peptide

What this is

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), designed in the 1980s and 1990s by Mac Hadley, Victor Hruby, and colleagues at the University of Arizona. The cyclic structure makes it more resistant to breakdown than native α-MSH and extends its activity in the body. It is a non-selective agonist across the melanocortin-receptor family — active at MC1R, MC3R, MC4R, and MC5R, with weak MC2R interaction — which means it simultaneously drives skin tanning, appetite suppression, and sexual arousal through distinct receptor pathways.

The raw stored sequence LDHFRWK represents the canonical α-MSH core residues; the actual compound is the cyclized, modified form Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ — N-terminally acetylated, C-terminally amidated, with norleucine (Nle) substituting at position 1, D-phenylalanine at position 4, and a lactam bridge cyclizing the Asp and Lys side chains. These modifications are responsible for its enhanced potency and metabolic stability compared with the linear parent hormone.

The original therapeutic hypothesis was pharmacological skin-cancer chemoprevention: stimulate endogenous melanin production rather than rely on UV exposure for tan-mediated UV protection. Commercial development was abandoned by Palatin Technologies around 2000 in favor of the more MC4R-selective derivative bremelanotide (PT-141), which later received FDA approval as Vyleesi for hypoactive sexual desire disorder. MT-II itself has never been approved anywhere and now circulates primarily as a gray-market compound. The closely named afamelanotide (Melanotan I, Scenesse) is a structurally distinct linear MC1R-selective peptide approved for erythropoietic protoporphyria and is not the same molecule (Ericson and colleagues 2017).

---

History

MT-II emerged from structure-activity relationship work on α-MSH carried out at the University of Arizona, with the goal of creating a more potent and metabolically stable melanocortin agonist. The cyclic lactam-bridged scaffold was a deliberate design choice to confer proteolytic resistance while retaining broad receptor activity. Early human pilot studies in the 1990s and around 2000 explored its erectogenic and pigmentation effects, most notably the work of Wessells and colleagues, who conducted double-blind placebo-controlled crossover studies in men with erectile dysfunction (Wessells and colleagues 2000). Development as a pharmaceutical was discontinued in favour of selective derivatives; bremelanotide (PT-141), derived from MT-II by ring opening and structural refinement, progressed through clinical development and ultimately gained regulatory approval. The comprehensive review by Ericson and colleagues (2017) in Biochimica et Biophysica Acta covers the trajectory of melanocortin ligands from 1954 through 2016, including MT-II's place in that history.

MT-II never left Phase I/pilot stage for any indication. After development was abandoned, it entered gray-market distribution—marketed online for tanning and sexual effects, often labeled as a "research chemical not for human use."

---

What it does

MT-II activates melanocortin receptors throughout the body, producing several simultaneous effects:

• Skin darkening (tanning): Stimulation of MC1R on melanocytes drives eumelanin synthesis, producing pigmentation without UV exposure.
• Sexual arousal and erection: Activation of MC4R (and MC3R) in the hypothalamus and limbic system drives central pro-erectile signaling. Wessells and colleagues (2000) reported spontaneous erections in 17 of 20 men with erectile dysfunction in a placebo-controlled crossover study, with heightened sexual desire in 68% of active-treatment doses versus 19% for placebo.
• Appetite suppression: MC4R activation in the hypothalamus suppresses food intake; this effect is documented in rodent models and described in broader melanocortin-system reviews (Ericson and colleagues 2017).
• Other melanocortin effects: MC5R activity in sebaceous glands and MC3R in adipose tissue contribute to less well-characterized effects on skin lipids and energy balance.

Because MT-II activates multiple receptor subtypes simultaneously, the tanning, sexual-arousal, and appetite effects are bundled together and cannot be readily separated by this compound. More selective analogs — bremelanotide for MC4R, afamelanotide for MC1R — were developed precisely to disaggregate these effects.

---

Evidence

• Human: Small Phase I and pilot placebo-controlled crossover studies from the 1990s and 2000 demonstrated spontaneous erections and heightened sexual desire in men with erectile dysfunction (Wessells and colleagues 2000), and pigmentation effects in early evaluations. Diamond and colleagues (2006) studied bremelanotide (the PT-141 derivative) in premenopausal women with sexual arousal disorder, showing subjective sexual response to MC3R/MC4R agonism — this is the more clinical cousin rather than MT-II directly. No completed Phase II or Phase III efficacy trial exists for MT-II for any indication. A substantial body of human data now consists of case reports rather than controlled trials.
• Animal: Rodent studies document melanogenesis, appetite suppression, central pro-erectile effects (intracerebroventricular administration produces erections in rats), and thermogenic activity in brown fat. The available literature describes non-selective MCR agonism as well-characterized mechanistically in animal models.
• In vitro: Receptor binding and selectivity profiling across MC1R–MC5R is documented; the broad non-selective receptor-activation profile is established.

---

Known effects

• Skin pigmentation (tanning) — Human pilot evidence; mechanism strong (MC1R/eumelanin)
• Penile erection and sexual arousal — Human Phase I / placebo-controlled crossover (Wessells and colleagues 2000); effect established in early studies, program not continued to efficacy stage
• Appetite suppression — Animal models; early human pilot signals; not validated in efficacy trials
• Nausea and yawning — Human clinical studies and case reports; common dose-related effects
• Eruptive nevi and mole darkening — Multiple published case reports; onset within weeks of use; not always reversible on discontinuation
• Spontaneous erection / priapism — Human pilot trials and case-series reports

---

Safety signals

The safety profile of MT-II is characterized by a cluster of common nuisance effects (nausea, flushing, yawning) documented in controlled pilot studies, and a more serious set of signals arising from case reports of gray-market use:

• Nausea and facial flushing — Common in controlled pilot studies; Wessells and colleagues (2000) reported nausea in 38% of subjects but no severe nausea with both administrations in any individual; symptoms reduced on second dosing in most instances.
• Spontaneous erections and priapism — Desired effect in early trials; case-series reports describe priapism (prolonged unwanted erection requiring medical attention) in gray-market use.
• Darkening of existing nevi and eruptive new nevi — Documented in multiple published case reports within weeks of starting use; the available literature indicates not all changes reverse after discontinuation.
• Rhabdomyolysis and renal dysfunction — A published clinical toxicology case report describes subcutaneous MT-II injection leading to systemic toxicity with sympathomimetic excess, renal dysfunction, and rhabdomyolysis.
• Renal infarction — At least one published case report describes renal infarction temporally associated with MT-II use; the available literature describes this as a first documented case of possible direct toxic effects on renal parenchyma.
• Mucosal hyperpigmentation and oral mucosal melanoma — Case reports describe hyperpigmentation of lips, gums, and oral mucosa with sustained use; one published case report links nasal-spray use specifically to anterior-maxilla mucosal malignant melanoma.
• Cutaneous melanoma — Five or more published case reports document melanoma during or after MT-II use; the available literature notes that causal attribution is contested, with increased sun-seeking behavior proposed as a contributing factor.
• Cardiovascular and blood-pressure effects — Melanocortin agonism can affect vascular tone; ischemic events appear in case reports.
• Product-quality risks — Analytical studies of black-market MT-II products document contamination, mislabeling, and identity confusion with bremelanotide; adverse events in gray-market users may partly reflect contaminants rather than MT-II itself.

No long-term prospective human safety data exist. The available literature notes several populations of concern based on biological plausibility and case-report patterns: personal or family history of melanoma, atypical mole syndrome, extensive nevus burden, and cardiovascular disease. These reflect compiled-source caution language from reviews and case-series, not regulator-issued labeling.

---

Regulatory status

• US (FDA): Not approved for any indication. The FDA has issued warning letters to vendors marketing MT-II. The related compound afamelanotide (Scenesse, Melanotan I) is FDA-approved for erythropoietic protoporphyria — it is a different molecule.
• UK (MHRA): Not approved; the MHRA has prosecuted unlicensed sellers per the available literature.
• EU / EMA: Not authorized. Multiple EU member-state agencies (including Swedish, Finnish, and Norwegian regulators) have issued consumer warnings.
• Australia (TGA): Unapproved therapeutic good; the TGA has taken enforcement action; Australian dermatology societies have flagged MT-II as a public-health concern.
• WADA: Not individually named on the Prohibited List, but covered under the S0 category (substances not approved by any governmental regulatory health authority for human therapeutic use); athletes subject to WADA, USADA, or UKAD should treat MT-II as prohibited under S0.

MT-II is sold through research-chemical channels labeled "not for human use." This labeling does not constitute regulatory authorization or quality control. Analytical studies have documented contamination and identity confusion with bremelanotide in gray-market products.

---

Mechanism

MT-II is a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with weaker activity at MC2R. Its full chemical structure is Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂: a seven-residue lactam-bridged cyclic peptide with an N-terminal acetyl cap, a C-terminal amide, norleucine (Nle) replacing methionine at position 1, and D-phenylalanine replacing L-Phe at position 4. Molecular formula C₅₀H₆₉N₁₅O₉; molecular weight approximately 1024.2 g/mol. The plasma half-life is reported as approximately 30–60 minutes in the available literature — substantially longer than native α-MSH, which is degraded within minutes. Neither the acetyl cap, the amide, the norleucine substitution, the D-Phe, nor the lactam bridge is represented in the raw stored sequence LDHFRWK.

Receptor-level effects:

• MC1R on melanocytes: activates the cAMP pathway, driving tyrosinase activity and eumelanin synthesis — the mechanism underlying the tanning effect.
• MC4R in the hypothalamus and limbic system: suppresses appetite via central hypothalamic circuits, and drives the pro-erectile and sexual-arousal effects; intracerebroventricular administration in rats produces erections, while intracavernous injection does not — confirming central rather than peripheral mediation (Wessells and colleagues 2000). This pathway is the pharmacological target of the FDA-approved derivative bremelanotide (PT-141).
• MC3R in the hypothalamus and limbic system: contributes additional regulation of feeding and arousal.
• MC5R in sebaceous glands: less clearly characterized; may influence skin-lipid secretion.
• MC2R (ACTH receptor): weak interaction; not the primary pharmacology.

The broad non-selective activation profile produces the simultaneous bundle of tanning, appetite, and sexual effects, and is also responsible for the wider adverse-effect burden relative to selective analogs. The conversion of Met to Nle and Phe to D-Phe in α-MSH that defines MT-II's scaffold was identified through structure-activity relationship work reviewed comprehensively by Ericson and colleagues (2017).

---

Related peptides

• Bremelanotide (PT-141, Vyleesi) — MC4R-selective derivative of MT-II; FDA-approved for hypoactive sexual desire disorder in premenopausal women; the direct descendant of MT-II's development program
• Afamelanotide (Melanotan I, Scenesse) — linear, relatively MC1R-selective analog; licensed as an orphan drug for erythropoietic protoporphyria and solar urticaria; not the same molecule as MT-II despite the similar naming

---

Open questions

• Long-term melanocyte and skin-cancer risk: No prospective long-term study addresses whether chronic non-selective melanocortin agonism, documented eruptive nevi, and mole darkening translate into measurable melanoma risk. Reversibility of these changes on discontinuation is not well characterized.
• Route-specific safety (nasal spray): A published case of mucosal melanoma after nasal-spray use, plus oral-mucosa pigmentation reports, raise route-specific questions not addressed by any controlled study.
• Cardiovascular signal: Renal infarction and ischemic events appear in case reports; systematic cardiovascular characterization for MT-II is not established.
• Product identity in the gray-market supply: Analytical studies document contamination and identity confusion with bremelanotide; clinical consequences of mislabeled products are not quantified.
• Neuropsychiatric effects: Empathogenic and mood-altering effects reported by users have not been prospectively studied.
• Selective vs. non-selective trade-offs: Whether MC4R-selective (bremelanotide) or MC1R-selective (afamelanotide) analogs fully capture the relevant benefits of MT-II without its broader side-effect burden is partially but not fully resolved by existing evidence.